SC
NPCE icon

Steven Cohen’s Neuropace NPCE Stock Holding History

Steven Cohen’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-152,025
Closed -$2M – 4413
2026
Q1 		$2M Buy
152,025
+127,384
+517% +$1.91M ﹤0.01% 2305
2025
Q4 		$380K Buy
+24,641
New +$330K ﹤0.01% 3375
2025
Q1 		– Sell
-32,943
Closed -$369K – 2369
2024
Q4 		$369K Buy
+32,943
New +$286K ﹤0.01% 1739
2022
Q4 		– Sell
-145,703
Closed -$546K – 1706
2022
Q3 		$546K Sell
145,703
-3,496
-2% -$16.9K ﹤0.01% 1149
2022
Q2 		$739K Sell
149,199
-59,977
-29% -$396K ﹤0.01% 1130
2022
Q1 		$1.72M Buy
209,176
+72,976
+54% +$630K 0.01% 895
2021
Q4 		$1.37M Buy
+136,200
New +$1.77M 0.01% 869

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Steven Cohen's NPCE Position: Q2 2026 in Review

Steven Cohen sold out of Neuropace (NPCE) in Q2 2026, closing a stake of 152,025 shares — an estimated $2M sold.

Steven Cohen first reported a position in NPCE in Q4 2021 and held it in 7 quarters. The position peaked at $2M in Q1 2026. 112 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Steven Cohen reported no remaining Neuropace position as of Q2 2026 after selling out during the quarter.
  • Steven Cohen sold 152,025 Neuropace shares in Q2 2026, an estimated $2M.
  • Steven Cohen first reported a position in Neuropace in Q4 2021 and held it in 7 quarters.
  • Steven Cohen's Neuropace position peaked at $2M in Q1 2026.
  • 112 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.